Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
October 1, 2009
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside
Elizabeth J Rahn, Andrea G Hohmann
Therapeutic Advances in Musculoskeletal Disease
|
October 1, 2019
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice
Giovanni Adami, Elizabeth J Rahn, Kenneth G Saag
Neurobiology of Learning and Memory
|
June 26, 2013
Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory
Elizabeth J Rahn, Mikael C Guzman-Karlsson, J David Sweatt
Frontiers in Psychology
|
November 12, 2015
Do long delay conditioned stimuli develop inhibitory properties?
Martha Escobar, W T Suits, Elizabeth J Rahn, et al.
Expert Opinion on Drug Safety
|
August 1, 2020
Cardiovascular safety risks associated with gout treatments
Giovanna Rosas, Angelo Gaffo, Elizabeth J Rahn, et al.
The AAPS Journal
|
February 4, 2010
Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation
Elizabeth J Rahn, Alexander M Zvonok, Alexandros Makriyannis, et al.
Biology of Sex Differences
|
March 4, 2014
Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus
Elizabeth J Rahn, Tommaso Iannitti, Renee R Donahue, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 31, 2008
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats
Elizabeth J Rahn, Alexander M Zvonok, Ganesh A Thakur, et al.
Pharmacology, Biochemistry, and Behavior
|
March 9, 2011
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects
Elizabeth J Rahn, Ganesh A Thakur, Jodi Anne T Wood, et al.
Research in Social & Administrative Pharmacy : RSAP
|
October 4, 2020
Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use
Michael J Miller, Tzuchen Jou, Maria I Danila, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
October 1, 2009
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside
Elizabeth J Rahn, Andrea G Hohmann
Therapeutic Advances in Musculoskeletal Disease
|
October 1, 2019
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice
Giovanni Adami, Elizabeth J Rahn, Kenneth G Saag
Neurobiology of Learning and Memory
|
June 26, 2013
Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory
Elizabeth J Rahn, Mikael C Guzman-Karlsson, J David Sweatt
Frontiers in Psychology
|
November 12, 2015
Do long delay conditioned stimuli develop inhibitory properties?
Martha Escobar, W T Suits, Elizabeth J Rahn, et al.
Expert Opinion on Drug Safety
|
August 1, 2020
Cardiovascular safety risks associated with gout treatments
Giovanna Rosas, Angelo Gaffo, Elizabeth J Rahn, et al.
The AAPS Journal
|
February 4, 2010
Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation
Elizabeth J Rahn, Alexander M Zvonok, Alexandros Makriyannis, et al.
Biology of Sex Differences
|
March 4, 2014
Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus
Elizabeth J Rahn, Tommaso Iannitti, Renee R Donahue, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 31, 2008
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats
Elizabeth J Rahn, Alexander M Zvonok, Ganesh A Thakur, et al.
Pharmacology, Biochemistry, and Behavior
|
March 9, 2011
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects
Elizabeth J Rahn, Ganesh A Thakur, Jodi Anne T Wood, et al.
Research in Social & Administrative Pharmacy : RSAP
|
October 4, 2020
Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use
Michael J Miller, Tzuchen Jou, Maria I Danila, et al.
Page
of 3